Understanding how T-cells cause heart inflammation from cancer treatments
Identification of Causal T-Cell Mechanisms in Immune Checkpoint Inhibitor Induced Myocarditis
This study is looking into how certain cancer treatments can sometimes cause heart inflammation, and it aims to understand how specific immune cells might be causing this issue, so we can find better ways to protect the heart for patients undergoing these therapies.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11007197 on NIH RePORTER |
What this research studies
This research investigates the mechanisms by which immune checkpoint inhibitors, used in cancer therapy, can lead to myocarditis, a serious inflammation of the heart. The study focuses on the role of specific T-cells that may become overly activated and cause damage to the heart tissue. By utilizing advanced techniques like single-cell RNA sequencing and T-cell transfer experiments, the researchers aim to identify the pathways involved in this adverse effect. This could help in developing strategies to prevent or manage heart complications in patients receiving these cancer treatments.
Who could benefit from this research
Good fit: Ideal candidates for this research include patients with advanced cancer who are receiving immune checkpoint inhibitors and may be at risk for myocarditis.
Not a fit: Patients who are not receiving immune checkpoint inhibitors or do not have advanced cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved safety and management strategies for patients undergoing cancer treatment with immune checkpoint inhibitors.
How similar studies have performed: While the specific mechanisms of T-cell induced myocarditis are still being explored, there is ongoing research into immune-related adverse events from cancer therapies, indicating a growing understanding of this area.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Zhu, Han — Stanford University
- Study coordinator: Zhu, Han
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.